Safety and Tolerability Clinical Trial
Official title:
A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose, Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Study of DP13 in Healthy Male Subjects
Primary Objectives:
1. To determine the safety and tolerability of single and multiple oral doses of DP13 in
healthy male subjects
2. To assess the pharmacodynamics of single and multiple ascending oral doses as well as
dosing regimen of DP13 on suppression of serum aldosterone in healthy male subjects
Secondary Objectives:
1. To determine the single and multiple oral dose pharmacokinetics of DP13 in healthy male
subjects
2. To determine the dose-dependent pharmacodynamic selectivity of DP13 in healthy male
subjects
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06000891 -
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
|
Phase 1 | |
| Active, not recruiting |
NCT05997641 -
Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06181760 -
A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT05907382 -
Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01952548 -
Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers
|
Phase 1 | |
| Completed |
NCT05431634 -
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants
|
Phase 1 | |
| Recruiting |
NCT06331884 -
Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)
|
Phase 1 | |
| Recruiting |
NCT06079541 -
Phase 1 Clinical Study of JMKX003142 Tablets
|
Phase 1 | |
| Completed |
NCT05223660 -
A Phase I Pharmacokinetics Study for KT07 Capsule
|
Phase 1 | |
| Completed |
NCT01907867 -
Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin
|
Phase 1 | |
| Completed |
NCT03809052 -
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03853421 -
Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin
|
Phase 1 | |
| Terminated |
NCT03307512 -
PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD
|
Phase 2 | |
| Completed |
NCT03685708 -
HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
|
Phase 2 | |
| Completed |
NCT03702231 -
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
|
Phase 2 | |
| Completed |
NCT03817346 -
Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT01226316 -
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
|
Phase 1 | |
| Completed |
NCT05451667 -
Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02029482 -
Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects
|
Phase 1 |